perphenazine
Trade name: trilafon
Approved
Feb 27, 1957
Perphenazine is a typical antipsychotic drug. Chemically, it is classified as a piperazinyl phenothiazine. Originally marketed in the United States as Trilafon, it has been in clinical use for decades. — Wikipedia
Clinical trial activity
23 trials · 30 clinical orgs · 25 marketing orgs
Earliest trial started Sep 1, 1995 (NCT00009204)
Timeline
1950s
- Feb 27, 1957
Schering-Plough — Earliest FDA Approval
- Feb 27, 1957
Schering — NDA Secondary Org
- Feb 27, 1957
Schering-Plough — NDA Organization
1960s
- Aug 23, 1965
New River Pharmaceuticals — Marketing Organization
- Aug 23, 1965
New River Pharmaceuticals — NDA Secondary Org
1980s
- Nov 12, 1986
Sun Pharmaceuticals — Marketing Organization
- Mar 2, 1987
Watson Pharmaceuticals — Marketing Organization
- Sep 10, 1987
Ani Pharmaceuticals — Marketing Organization
- Nov 27, 1987
Fosun — Marketing Organization
- Nov 10, 1988
Mylan — Marketing Organization
- Dec 8, 1988
Sandoz — Marketing Organization
1990s
- Oct 17, 1991
Heritage Pharma — Marketing Organization
- Oct 17, 1991
Chartwell Pharmaceuticals — Marketing Organization
- Jan 1, 1995
Earliest Phase 3 Sponsor(trial)
- Dec 31, 1998
Vintage — Marketing Organization
- Dec 31, 1998
Endo Pharmaceuticals — Marketing Organization
- Dec 31, 1998
PH HEALTH — Marketing Organization
2000s
- May 25, 2001
Pharmaceutical Associates — Marketing Organization
- Jan 1, 2007
Earliest Phase 1 Sponsor(trial)
- Jan 1, 2007
Earliest Phase 2 Sponsor(trial)
2010s
- Dec 17, 2015
Wilshire Pharmaceuticals — Marketing Organization
- Oct 17, 2016
Allergan PLC (2015) — Marketing Organization
- Mar 1, 2019
Rising Pharmaceuticals — Marketing Organization
- Mar 1, 2019
ANDA Repository — Marketing Organization
2020s
- Apr 6, 2020
Zydus Discovery DMCC — Marketing Organization
- May 18, 2022
Appco Pharma — Marketing Organization
- May 6, 2024
Macleods Pharmaceuticals, Ltd — Marketing Organization
- Mar 18, 2025
Jubilant Innovation Ltd. — Marketing Organization
Indications
Studied for
- Alzheimer Disease · Phase 3
- Anxiety Disorders · Phase 3
- Cocaine-Related Disorders · Phase 2
- Dementia · Phase 3
- Dementia, Vascular · Phase 3
- Depression · Phase 3
- Drug Interactions · Phase 1
- General Surgery · Phase 3
- Healthy Volunteers · Phase 1
- Ischemic Stroke · Phase 2
- Mental Health · Phase 3
- Psychophysiologic Disorders · Phase 3
- Psychotic Disorders · Phase 4
- Schizophrenia Spectrum and Other Psychotic Disorders · Phase 4
Mechanism of action
- Dopamine D2 receptorANTAGONIST
DRD2 antagonist
Combination products
triavil
with amitriptyline
Also known as etrafon, etrafon-a, etrafon-forte
Approval history
- approvedFeb 27, 1957
Chemistry & pharmacology
SMILES
OCCN1CCN(CCCN2C3=CC=CC=C3SC4=CC=C(Cl)C=C24)CC1- Mol. weight
- 403.969 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Availability
- Prescription Only
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPerphenazine ↗
- NCATSFTA7XXY4EZ ↗
- ChEMBLCHEMBL567 ↗
- ChEMBLCHEMBL1697766 ↗
Also known as
- 2-(4-[3-(2-chloro-10h-phenothiazin-10-yl)propyl]-1-piperazinyl)ethanol
- 2-(4-[3-(2-chloro-10h-phenothiazin-10-yl)propyl]-1-piperazinyl)ethanol
- 2-chloro-10-(3-(4-(2-hydroxyethyl)piperazin-1-yl)propyl)phenothiazine
- 2-chloro-10-(3-(4-(2-hydroxyethyl)piperazin-1-yl)propyl)phenothiazine
- 4-[3-(2-chloro-10h-phenothiazin-10-yl)propyl]-1-piperazineethanol
- 4-[3-(2-chloro-10h-phenothiazin-10-yl)propyl]-1-piperazineethanol
- 4-[3-(2-chlorophenothiazin-10-yl)propyl]-1-piperazineethanol
- 4-[3-(2-chlorophenothiazin-10-yl)propyl]-1-piperazineethanol
- bl1020
- bl 1020
- bl-1020
- bl-1020
- bl-1020
- bl-1020
- chlorpiprazine
- chlorpiprazine
- chlorpiprazine
- cyp-1020
- decentan
- decentan
- etaperazin
- etaperazin
- etaperazine
- etaperazine
- etaperazine
- ethaperazine
- ethaperazine
- fentazin
- fentazin
- gamma-(4-(beta-hydroxyethyl)piperazin-1-yl)propyl-2-chlorophenothiazine
- gamma-(4-(beta-hydroxyethyl)piperazin-1-yl)propyl-2-chlorophenothiazine
- perazine
- perazine
- perazine
- perazine
- perazine
- perazine
- perazine
- perfenazina
- perfenazina
- perfenazine
- perfenazine
- perfenazine
- perfenazine
- perfenil
- pernazine
- perphanzine
- perphenan
- perphenazin
- perphenazin
- perphenazin
- perphenazine
- perphenazine
- perphenazine
- perphenazine
- perphenazine
- perphenazine
- perphenazine
- perphenazine
- perphenazine
- perphenazine
- perphenazine
- perphénazine
- perphénazine
- perphenazine fendizoate
- perphenazine fendizoate
- perphenazine gaba ester
- perphenazine maleate
- perphenazine maleate
- perphenazinum
- perphenazinum
- thilatazin
- tranquisan
- trilafon
- trilafon
- trilafon
- trilafon-la
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05762146 | Phase 2 | Sep 5, 2022 | Maastricht University |
| NCT04776499 | Phase 1 | Mar 18, 2021 | European Commission, Maastricht University, University of Heidelberg |
| NCT04606264 | Phase 3 | Jan 1, 2021 | Berry Consultants, University of Pittsburgh |
| NCT02431702 | Phase 3 | Jul 8, 2015 | Janssen Pharmaceutica NV, Johnson and Johnson |
| NCT02374567 | Phase 3 | Jan 1, 2015 | Gottfried Wilhelm Leibniz Universität Hannover |
| NCT02307396 | Phase 4 | Nov 1, 2014 | Technical University of Munich |
| NCT02199743 | Phase 4 | Feb 1, 2013 | Sunovion, The University of Texas, Dallas |
| NCT01765829 | Phase 3 | Nov 1, 2012 | Government of Spain, Universidad Carlos III Madrid |
| NCT02192723 | N/A | Jun 1, 2012 | Peking University |
| NCT01363349 | Phase 2/Phase 3 (Phase 3) | May 1, 2011 | BioLineRx, Ltd. |
| NCT03019887 | N/A | Apr 1, 2011 | Juntendo University |
| NCT01193166 | Phase 4 | Aug 1, 2010 | Johnson and Johnson |
| NCT01157351 | Phase 4 | May 1, 2010 | Janssen Pharmaceutica NV, Johnson and Johnson |
| NCT00806234 | Phase 4 | Jan 1, 2009 | Johns Hopkins University, National Institute of Mental Health (NIMH), The Zucker Hillside Hospital, University of Maryland, University of North Carolina at Chapel Hill |
| NCT00802100 | Phase 4 | Dec 1, 2008 | Duke University, National Institute of Mental Health (NIMH), University of North Carolina at Chapel Hill |
| NCT00737256 | Phase 2 | Aug 1, 2008 | Denver Research Institute, Department of Veteran Affairs |
| NCT00567710 | Phase 2 | Jul 1, 2008 | BioLineRx, Ltd. |
| NCT00722176 | Phase 2 | Jun 1, 2008 | BioLineRx, Ltd. |
| NCT00480571 | Phase 2 | Jun 1, 2007 | BioLineRx, Ltd., Tel Aviv University |
| NCT00480246 | Phase 1 | May 1, 2007 | BioLineRx, Ltd., IQVIA |
Organizations
Research & Development (30)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| BioLineRx, Ltd. | For profit | 5 | 5 | 3 | 2007 |
| National Institute of Mental Health (NIMH) | Government | 4 | 2 | 2 | 1995 |
| Johnson and Johnson | For profit | 3 | 3 | 2 | 2010 |
| University of North Carolina at Chapel Hill | Academic/Hospital | 3 | 0 | 1 | 2000 |
| Janssen Pharmaceutica NV | For profit | 2 | 0 | 2 | 2010 |
| Maastricht University | Academic/Hospital | 2 | 2 | 2 | 2021 |
| University of Pittsburgh | Academic/Hospital | 2 | 1 | 1 | 1995 |
| Berry Consultants | For profit | 1 | 0 | 1 | 2021 |
| Canadian Psychiatric Research Foundation | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Denver Research Institute | Academic/Hospital | 1 | 1 | 1 | 2008 |
| Department of Veteran Affairs | Government | 1 | 0 | 1 | 2008 |
| Duke University | Academic/Hospital | 1 | 0 | 1 | 2008 |
| European Commission | Government | 1 | 0 | 1 | 2021 |
| Gottfried Wilhelm Leibniz Universität Hannover | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Government of Spain | Government | 1 | 1 | 1 | 2012 |
| IQVIA | For profit | 1 | 0 | 1 | 2007 |
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2009 |
| Juntendo University | Academic/Hospital | 1 | 1 | 1 | 2011 |
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 1995 |
| Peking University | Academic/Hospital | 1 | 1 | 1 | 2012 |
Marketing (30)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| ANDA Repository | For profit | MKTG | Mar 1, 2019 |
| Allergan PLC (2015) | For profit | MKTG | Oct 17, 2016 |
| Ani Pharmaceuticals | For profit | MKTG | Sep 10, 1987 |
| Ani Pharmaceuticals | For profit | SYN | Sep 10, 1987 |
| Appco Pharma | For profit | MKTG | May 18, 2022 |
| Chartwell Pharmaceuticals | For profit | MKTG | Oct 17, 1991 |
| Endo Pharmaceuticals | For profit | MKTG | Dec 31, 1998 |
| Fosun | For profit | MKTG | Nov 27, 1987 |
| Heritage Pharma | For profit | MKTG | Oct 17, 1991 |
| Jubilant Innovation Ltd. | For profit | MKTG | Mar 18, 2025 |
| Macleods Pharmaceuticals, Ltd | For profit | MKTG | May 6, 2024 |
| Mylan | For profit | MKTG | Nov 10, 1988 |
| Mylan | For profit | SYN | Apr 14, 2017 |
| New River Pharmaceuticals | For profit | MKTG | Aug 23, 1965 |
| New River Pharmaceuticals | For profit | NDA2 | Aug 23, 1965 |
| PH HEALTH | For profit | MKTG | Dec 31, 1998 |
| Par Pharmaceuticals | For profit | MKTG | — |
| Pharmaceutical Associates | For profit | MKTG | May 25, 2001 |
| Rising Pharmaceuticals | For profit | MKTG | Mar 1, 2019 |
| Rising Pharmaceuticals | For profit | SYN | Mar 1, 2019 |
| Sandoz | For profit | MKTG | Dec 8, 1988 |
| Schering | For profit | NDA2 | Feb 27, 1957 |
| Schering-Plough | For profit | NDA | Feb 27, 1957 |
| Sun Pharmaceuticals | For profit | MKTG | Nov 12, 1986 |
| Teva | For profit | MKTG | — |
| Vintage | For profit | MKTG | Dec 31, 1998 |
| Watson Pharmaceuticals | For profit | MKTG | Mar 2, 1987 |
| Watson Pharmaceuticals | For profit | SYN | Oct 17, 2016 |
| Wilshire Pharmaceuticals | For profit | MKTG | Dec 17, 2015 |
| Zydus Discovery DMCC | For profit | MKTG | Apr 6, 2020 |